Outcome of Board Meeting held on April 27, 2026.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech reported audited consolidated results for FY2026 with revenue of Rs 23,963.65 million (up 15.2% from Rs 20,802.94 million in FY2025) and profit after tax of Rs 1,492.13 million (up 9.4% from Rs 1,363.78 million). Q4 standalone revenue was Rs 6,848.62 million with PAT of Rs 459.67 million. The Board declared a final dividend of Rs 0.50 per share (25% on face value Rs 2), subject to shareholder approval at AGM. Mr. Udeypaul Singh Gill was appointed as Non-Executive Independent Director for 3 years effective April 28, 2026. The company allotted 8,250 equity shares under ESOP 2019 at Rs 425 per share, increasing paid-up capital to Rs 11.08 crore. The capacity expansion project is being rescheduled to a phased approach over two years due to evolving business conditions. A new R&D facility has been set up in Navi Mumbai, with the existing IIT Bombay R&D unit being relocated there.
Strong financial performance with 15% revenue growth and 9% PAT growth. Dividend declaration provides income to shareholders. Capacity expansion delay may impact near-term growth timeline, while new R&D facility could enhance long-term innovation capabilities.